Thorsten Degenhardt has over 10 years of experience in the pharmaceutical and biotechnology industry. Most recently he was Project Director at BioStratum, Inc., and was responsible for moving its lead drug candidate from early preclinical development through the completion of Phase 2 studies. He was instrumental in establishing a second-generation program and assisted with the creation and implementation of development plans for the companies' other drug candidates. Prior to joining BioStratum, he worked with Dr. John Baynes at the University of South Carolina as a Research Assistant Professor on the identification and analysis of Advanced Glycation Endproducts that are implicated in the pathogenesis of diabetic complications. He received a M.S in Biochemistry from the Technical University of Darmstadt, Germany and subsequently obtained a Ph.D. in Pharmaceutical Chemistry in the area of diabetes and diabetic complications from the School of Pharmacy at the University of Heidelberg, Germany in a collaboration with Boehringer Mannheim. |